science

Otilimab

Otilimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Otilimab rather than just read about it. In short: Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies.

Key takeaways

Otilimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Otilimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Otilimab from memory before moving on to harder problems.

Reference excerpt

Otilimab (development codes MOR103 and GSK3196165) is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

Mode of action

Otilimab, as its monoclonal antibody, specifically binds to GM-CSF which is consequently neutralised and incapable of binding its targeted inflammatory cells as it should in order to allow their proliferation and activation. There is no following induction of inflammation (through cytokines e.g. TNF-α, IL-1, IL-6), chemotaxis (via chemokines e.g. IL-8), tissue degradation (caused by e.g. MMPs, H2O2) or T and B cell response (following up-regulated MHC II level).

Medical uses Beyond its role in natural immune pathways, GM-CSF has been shown to be involved in autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA) in which cases GM-CSF levels are elevated and mediate an increased production of pro-inflammatory elements (cytokines, chemokines, proteases). The factor is also known to be involved in osteoarthritis of the hand. Research has thus been working on it as a molecular target for the treatment of such disorders, notably through immunotherapy such as monoclonal antibody therapy which is known to be efficient against autoimmune diseases.

Rheumatoid arthritis There already exist treatments of rheumatoid arthritis through monoclonal antibodies (i.e. infliximab, adalimumab). These drugs are not targeting GM-CSF but TNF-α which is another cytokine involved in the disease. However, the major involvement of TNF-α in immunity makes its suppression delicate: it diminishes the immune defenses of treated patients against potential new infections and may allow the reactivation of latent ones such as hepatitis B and tuberculosis. The number of reported cases of severe side effects, including fatal ones, has led the FDA to instruct tight monitoring of patients before and during a treatment by TNF-inhibiting drugs. Nevertheless, another way to circumvent such outcomes may be to target an alternate cytokine.

Multiple sclerosis In multiple sclerosis (MS), GM-CSF is produced by T helper cells (Th1 and Th17). It is able to cross the blood-brain barrier (BBB) and bind to CD52 on macrophages surface. Along with other pro-inflammatory events, this will participate in the central nervous system (CNS) inflammation process typically occurring in MS. There are numerous existing monoclonal antibodies used in the treatment of multiple sclerosis: natalizumab (targets α4-integrin), daclizumab and alemtuzumab (both binding to CD25, the α-subunit of IL-2 receptor on the surface of mature lymphocytes), ocrelizumab (against CD20 marker on B-cells). However, the frequent adverse effects notified, including secondary autoimmune phenomena, suggest that the uncovering of a new molecular target for monoclonal antibody therapy would be welcomed in the research for an improved treatment against MS. Otilimab is currently undergoing clinical trials to determine whether it could be used as treatment and has so far shown to be generally well tolerated by both relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients. Indeed, most TEAEs (treatment-emergent adverse events) which were observed were mild to moderate. There isn't evidence of immunogenecity either: no anti-otilimab antibodies were detected in patients following treatment. These results provide Class I evidence in regards to acceptable tolerance in MS patients and reveal that otilimab remains a fitted candidate for the treatment of multiple sclerosis

References

Worked examples

Example 1 — a first encounter with Otilimab

Start with the simplest possible case. Write down what Otilimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Otilimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Otilimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Otilimab

In research: Otilimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Otilimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Otilimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Arthritis, Monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Otilimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Otilimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Otilimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Otilimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Otilimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Otilimab in simple terms?

Why does Otilimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Otilimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Otilimab.